ArticleJournal of molecular medicine (Berlin, Germany)2010
IL-2 -330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs).
Article in Journal of molecular medicine (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study.Scientific reports · 2016Trial
- Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Trial
- Review
- Role of Mediterranean diet in endocrine diseases: a joint overview by the endocrinologist and the nutritionist.Journal of endocrinological investigation · 2024Review
- Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms.Biomedicines · 2022Review
- Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors-Potential Clinical Relevance.Journal of clinical medicine · 2022Article
- Genome-wide association study of serum tumor markers in Southern Chinese Han population.BMC cancer · 2022Article
- IL-1RN VNTR, IL-2(-330), and IL-4 VNTR gene polymorphisms in patients with chronic rhinosinusitis with sinonasal polyposisTurkish journal of medical sciences · 2019Article
- Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Role of tumor microenvironment in tumorigenesis.Journal of Cancer · 2017Review
- Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors.Scientific reports · 2016Article
- Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center.Journal of gastroenterology · 2016Article
- Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis.OncoTargets and therapy · 2016Article
- IL-2 -330T/G polymorphism and cancer risk: a meta-analysis.OncoTargets and therapy · 2015Article
- Polymorphic variant at the IL2 region is associated with type 1 diabetes and may affect serum levels of interleukin-2.Molecular biology reports · 2013Article
- Genetic associations with sporadic neuroendocrine tumor risk.Carcinogenesis · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines participate in tumorigenesis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Single nucleotide polymorphisms (SNPs) in cytokine genes influence expression of proteins and are evaluated in cancer susceptibility. The aim of this study was to evaluate IL-2 -330 T/G SNP and susceptibility to GEP-NETs, and analyze the correlation between G-allele and IL-2 serum values in GEP-NET patients. Moreover we assessed the value of IL-2 as a tumor serum marker. IL-2 -330 T/G SNP was examined in 101 patients and 150 healthy volunteers and IL-2 serum levels in patients and 20 controls. Patients' IL-2 serum levels were compared to IL-2 -330 T/G genotypes and tumor functional status and finally with known markers such as chromogranin A (CgA) and 5-hydroxyindolacetic acid (5-HIAA). There was a significant difference in genotype distribution of the IL-2 -330 polymorphisms between GEP-NET and control group (p = 0.0006) as well as in the frequency of G-allele (p = 0.010). G-allele correlated with higher IL-2 serum levels (p = 0.028) and elevated in all patients, being highest in patients with functional tumors (p = 0.039). Compared to CgA and 5-HIAA, IL-2 was more specific in detecting GEP-NET patients (p < 0.0001 and p < 0.0001, respectively). Our results indicate importance of IL-2 in GEP-NET development and biochemical diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.